VJHemOnc is committed to improving our service to you

ISA 2020 | AL Amyloidosis: MRD negativity

VJHemOnc is committed to improving our service to you

Nelson Leung

Nelson Leung, MD, Mayo Clinic, Rochester, MN, discusses measurable residual disease (MRD) negativity in AL amyloidosis patients undergoing kidney transplantation. Dr Leung discusses a paper he co-authored investigating the impact of MRD negativity with Mass-Fix as a surrogate on the outcomes of AL amyloidosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter